biotech · Clostridium Difficile Infection · Autism Spectrum Disorder · FNCHQ
Finch Therapeutics Group
Finch Therapeutics is a biotech organization headquartered in Somerville, USA. It trades on NYSE under ticker FNCHQ. Primary therapeutic focus areas include Clostridium Difficile Infection, Autism Spectrum Disorder, Recu
Somerville, USA HQ
15 Employees
Public company Type
FNCHQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Somerville, USA
- Employees
- 15
- Programs
- 5
- Drugs
- 2
- Patents
- 33
Fecal Microbiota Transplantation
Phase 1 · mab · Enterobacteriaceae Infections
Fecal Microbiota Transplantation for Enterobacteriaceae Infections is a Phase 1 program (mab) at Finch Therapeutics Group with 1 ClinicalTrials.gov record(s).
Internal code 16-001946
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Finch Therapeutics Group
- Phase
- Phase 1
- Modality
- mab
- Indication
- Enterobacteriaceae Infections
- Status
- terminated
- Trials
- 1